Table 4.
Clinical trials of CAR-T cell therapy in cancer
| Target | ClinicalTrials.gov identifier | Cancer |
|---|---|---|
| TM4SF1 and EpCAM | NCT04151186 | Epithelial-derived solid tumors |
| c-Met/PD-L1 | NCT03672305 | Primary hepatocellular carcinoma |
| GPC3-T2 | NCT03198546 | Hepatocellular carcinoma |
| CTLA-4, PD-1, and MUC1 | NCT03179007 | Advanced solid tumor |
| NKG2D | NCT04270461 | Solid tumors |
| PD-1 and mesothelin | NCT03747965 | Solid tumors |
| CEA | NCT03682744 | Adenocarcinoma, peritoneal metastases, or malignant ascites |
| B7–H3 | NCT04185038 | Diffuse intrinsic pontine glioma/diffuse midline glioma and recurrent or refractory pediatric central nervous system tumors |
| MUC1 | NCT03525782 | NSCLC |
| EGFR | NCT03618381 | Recurrent/refractory solid tumors |
a
Abbreviations: CD, cluster of differentiation; CEA, carcinoembryonic antigen; EpCAM, epithelial cell adhesion molecule; TM4SF1, transmembrane 4 L six family member 1; c-Met, tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR); GPC3, glypican 3; MUC1, Mucin 1; NKG2D, natural killer group 2 member D.